LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regeneron Pharmaceuticals Inc

Cerrado

SectorSalud

492.82 2.13

Resumen

Variación precio

24h

Actual

Mínimo

481.24

Máximo

499.69

Métricas clave

By Trading Economics

Ingresos

-109M

809M

Ventas

-761M

3B

P/B

Media del Sector

12.47

51.198

BPA

8.22

Rentabilidad por dividendo

0.72

Margen de beneficio

26.701

Empleados

15,158

EBITDA

-54M

1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+46.86% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.72%

2.40%

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-22B

53B

Apertura anterior

490.69

Cierre anterior

492.82

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

117 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2025, 11:55 UTC

Adquisiciones, fusiones, absorciones

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29 abr 2025, 11:07 UTC

Ganancias

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 feb 2025, 12:13 UTC

Ganancias

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

5 jun 2025, 01:41 UTC

Adquisiciones, fusiones, absorciones

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 may 2025, 08:58 UTC

Acciones populares

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 may 2025, 08:56 UTC

Charlas de Mercado

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19 may 2025, 17:52 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 may 2025, 16:13 UTC

Adquisiciones, fusiones, absorciones

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 may 2025, 14:42 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 may 2025, 13:33 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19 may 2025, 11:10 UTC

Adquisiciones, fusiones, absorciones

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19 may 2025, 11:10 UTC

Adquisiciones, fusiones, absorciones

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19 may 2025, 11:09 UTC

Adquisiciones, fusiones, absorciones

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19 may 2025, 11:08 UTC

Adquisiciones, fusiones, absorciones

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29 abr 2025, 18:04 UTC

Charlas de Mercado
Ganancias

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 abr 2025, 14:39 UTC

Charlas de Mercado
Ganancias

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 abr 2025, 14:29 UTC

Ganancias

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 abr 2025, 13:11 UTC

Ganancias

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 abr 2025, 10:32 UTC

Ganancias

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 abr 2025, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Rev $3.03B >REGN

29 abr 2025, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Net $808.7M >REGN

29 abr 2025, 10:30 UTC

Ganancias

Regeneron Pharma 1Q EPS $7.27 >REGN

29 abr 2025, 10:30 UTC

Ganancias

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 abr 2025, 10:51 UTC

Principales Noticias

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Ganancias

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Ganancias

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Ganancias

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Ganancias

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Ganancias

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

46.86% repunte

Estimación a 12 meses

Media 724.35 USD  46.86%

Máximo 900 USD

Mínimo 535 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

23 ratings

17

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

542.44 / 599.76Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

117 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.